Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Arthritis is THE future market

<< Previous

Bullboard Posts

Next >>

Post by mstrmndon Jul 20, 2021 4:36pm

279 Views

Post# 33576707

Arthritis is THE future market

Muscle and fitness addictions are going to drive a huge rise in the future degenerative osteoarthritis market...this is THE future market and ATE.TO is incredibly well-positioned to not just be a part of it, but completely dominate it

Hold the line & say yes to vote out Dan at AGM

GLTA

<< Previous

Bullboard Posts

Next >>

Global Tungsten Market and Supply Security